Phase II Trial of EOquin in High-risk Superficial Bladder Cancer

Summary

A non-randomized, open-label phase II study to explore the feasibility, time to recurrence, duration of response and safety of the adjuvant intravesical instillation of EOquin (apaziquone) in patients with high-risk superficial bladder tumors, and the response and duration of response in patients with carcinoma in situ of the bladder.

Timeline

Start

2005-07

Primary completion

2009-12

Completion

2009-12

Drugs

Indications